Symbiotec Pharmalab's initial public offering (IPO) is set to open for subscription on August 24, 2026. According to the Red Herring Prospectus (RHP), the ₹1,757.00 crore book-built issue comprises a fresh issue of up to ₹150.00 crore and an offer for sale (OFS) of up to ₹1,607.00 crore by its existing shareholders.

The IPO will remain open until August 27, 2026, while the anchor investor portion will open for subscription on August 21, 2026. The basis of allotment is expected to be finalised on August 28, 2026, and the shares are tentatively scheduled to be listed on the BSE and NSE on September 1, 2026.

Symbiotec Pharmalab IPO - Issue Details

Issue Type: Book Built Issue (Fresh Issue + OFS)
Total Issue Size: Up to ₹1,757.00 crore
Fresh Issue: Up to ₹150.00 crore
Offer for Sale (OFS): Up to ₹1,607.00 crore
Face Value: ₹2 per equity share
Price Band: ₹938 to ₹988 per share
Lot Size: 15 shares
Minimum Investment Amount (Retail Investor): ₹14,820 (15 shares at the upper price)
Listing: BSE, NSE
Book Running Lead Managers: JM Financial Limited, Avendus Capital Private Limited, Motilal Oswal Investment Advisors Limited, Nomura Financial Advisory and Securities (India) Private Limited
Registrar: MUFG Intime India Private Limited

Symbiotec Pharmalab IPO Timeline (Tentative)

The expected IPO schedule is as follows:

Event	Date
Subscription Opening Date	24 August 2026
Subscription Closing Date	27 August 2026
Basis of Allotment Date	28 August 2026
Refund Initiation Date	31 August 2026
Credit of Shares	31 August 2026
Listing on BSE and NSE	1 September 2026

Note: The allotment and listing dates are tentative and may be revised.

Explore other Upcoming IPOs on BSE and NSE.

Symbiotec Pharmalab IPO Category-wise Investment Limits

The application size for each category is as follows -

Category	Investment Range
Qualified Institutional Buyers (QIBs)	Not more than 50% of the Net Issue
Non-Institutional Investors (NIIs)	Not less than 15% of the Net Issue
Retail Individual Investors (RII)	Not less than 35% of the Net Issue

The minimum investment amount for each category, based on the upper price band of ₹988 per share, is as follows -

Investor Category	Lots	Shares	Investment Amount (Approx.)
Retail (Minimum)	1	15	₹14,820
Retail (Maximum)	13	195	₹1,92,660
sNII (Minimum)	14	210	₹2,07,480
bNII (Minimum)	68	1,020	₹10,07,760

Utilisation of IPO Proceeds

The company intends to utilise the net proceeds from the fresh issue towards:

Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the company
General corporate purposes.

About Symbiotec Pharmalab Limited

Symbiotec Pharmalab Limited is a research and development-driven pharmaceutical and biotechnology company with expertise across organic chemistry, biotechnology, and complex injectables. The company is a global leader in corticosteroid and steroidal-hormone APIs by volume, holding a 38.2% share in corticosteroids and 23.8% in steroidal-hormone APIs in Fiscal 2026. Its portfolio includes over 60 APIs, supplied to regulated pharmaceutical markets worldwide.

The company operates a vertically integrated microbe-to-pharmacy and farm-to-pharmacy manufacturing platform, supported by industrial-scale API, fermentation, and injectable facilities in Madhya Pradesh. It also provides CDMO services to global pharmaceutical and nutraceutical companies, leveraging US FDA, EU-GMP, and other international regulatory approvals to serve innovators and generic drug manufacturers across highly regulated markets.

Key Financial Highlights

Particulars	FY26 (in ₹ crore)	FY25 (in ₹ crore)	FY24 (in ₹ crore)
Revenue from operations	869.15	751.55	716.25
EBITDA	231.97	206.11	177.04
Profit After Tax (PAT)	109.90	96.79	100.05